Muralidharan currently serves as Junior Research Fellow at Amrita School of Biotechnology. He also serves as the technology assistant at Amrita Agilent Analytical Research Centre, School of Biotechnology. He received his masters in Biotechnology from Amrita Vishwa Vidyapeetham University, Amritapuri in 2012. He is currently pursuing his doctoral degree in Biotechnology at Amrita Agilent Analytical Research Centre, School of Biotechnology.


  • MSc. Biotechnology, Amrita Vishwa Vidyapeetham University (2012).
  • Diploma in Bioinstrumentation, Bharathiar University (2010).
  • Bsc. Biotechnology, Bharathiar University (2010).


  • Junior Research Fellow at Amrita School of Biotechnology (current).
  • Technology Assistant, Amrita Agilent Analytical Research Centre (current).
  • Junior Research Fellow, Amrita Institute of Medical Sciences and Research Centre.


  • Awarded with Junior Research Fellowship from Amrita Vishwa Vidyapeetham University.
  • Qualified GATE-Biotechnology, March 2012.


  • Diabetes and Vascular Inflammation
  • Proteomics
  • Mass Spectrometry and High Performance Liquid Chromatography (HPLC) Techniques


  • Two month operator's training course for Agilent LC/MS: Agilent OpenLAB Chemstation, Agilent 1290 uHPLC, Agilent 6340 LC/MS Iontrap, Agilent 8354 UV-Visible Spectrometer, held at the Amrita Agilent Analytical Research Centre, Amrita School of Biotechnology from 5th August - 5th October,2013 headed by Dr.Walter Schrenk, Associate Professor, Amrita School of Biotechnology.
  • Development of Analytical methods in High Performance Chromatography, uHPLC, 2-Dimensional HPLC and Mass Spectrometry for the analysis, isolation and identification of active components out of plant extracts with potential medical uses under the guidance of Dr.Walter Schrenk and Dr.Sudarslal S, the Associate Professors at Amrita School of Biotechnology, from January to May 2014.



Muralidharan V.
Amrita Agilent Analytical Research Centre
School of Biotechnology
Amrita University (Amritapuri Campus)
Clappana P.O., Kollam, Kerala, India. 690525
Tel +91 (0)476-2803000 Extn:3126


Publication Type: Journal Article
Year of Publication Publication Type Title
2016 Journal Article D. Nair, Vanuopadath, M., Bipin G. Nair Dr., Gopalakrishnapai, J., and S, S., “Identification and characterization of a library of surfactins and fengycins from a marine endophytic Bacillus sp.”, Journal of Basic Microbiology, 2016.[Abstract]

An endophytic bacterial strain from a marine green alga, Ulva lactuca, was isolated and identified by 16S rRNA gene sequencing method. The bacterial isolate was found to secrete two major families of cyclic depsilipopeptides, surfactins, and fengycins. Sequencing of the isolated lipopeptides was carried out using the MS(n) data obtained from an electrospray ionization (ESI) ion trap mass spectrometer coupled to an HPLC system. The assigned sequences were confirmed by a chemical derivatization approach involving esterification followed by mass spectrometric analysis. Distinction of leucine residues from isoleucine was established through a combined electron transfer dissociation-collision-induced dissociation (ETD-CID) method. The fengycins described in this study were found to cause significant delay of growth of two plants, Vigna radiata (mung bean) and Oryza sativa (rice). To the best of our knowledge, this is the first study describing identification and characterization of cyclic peptides from an endophytic Bacillus sp. isolated from marine algae.

More »»
2015 Journal Article N. Mohammad, Singh, S. Vikram, Malvi, P., Chaube, B., Athavale, D., Vanuopadath, M., Nair, S. Sadasivan, Bipin G. Nair Dr., and Bhat, M. Kumar, “Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex”, Scientific reports (Article number 11853), vol. 5, 2015.[Abstract]

Doxorubicin (DOX) is one of the preferred drugs for treating breast and liver cancers. However, its clinical application is limited due to severe side effects and the accompanying drug resistance. In this context, we investigated the effect on therapeutic efficacy of DOX by cholesterol depleting agent methyl-β-cyclodextrin (MCD), and explored the involvement of p53. MCD sensitizes MCF-7 and Hepa1-6 cells to DOX, Combination of MCD and marginal dose of DOX reduces the cell viability, and promoted apoptosis through induction of pro-apoptotic protein, Bax, activation of caspase-8 and caspase-7, down regulation of anti-apoptotic protein Bcl-2 and finally promoting PARP cleavage. Mechanistically, sensitization to DOX by MCD was due to the induction of FasR/FasL pathway through p53 activation. Furthermore, inhibition of p53 by pharmacological inhibitor pifithrin-α (PFT-α) or its specific siRNA attenuated p53 function and down-regulated FasR/FasL, thereby preventing cell death. Animal experiments were performed using C57BL/6J mouse isografted with Hepa1-6 cells. Tumor growth was retarded and survival increased in mice administered MCD together with DOX to as compared to either agent alone. Collectively, these results suggest that MCD enhances the sensitivity to DOX for which wild type p53 is an important determinant.

More »»
Faculty Details


Faculty Email: